MAINTENANCE THERAPY IN MYELOMA - RISK VERSUS BENEFIT

被引：0
|
作者：
JACOBS, P [1 ]
DUBOVSKY, D [1 ]
KING, HS [1 ]
机构：
[1] UNIV CAPE TOWN,CAPE TOWN,SOUTH AFRICA
来源：
BRITISH MEDICAL JOURNAL | 1975年 / 3卷 / 5981期
关键词：
D O I：
10.1136/bmj.3.5981.490
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：490 / 490
页数：1
相关论文
共 50 条
  • [21] Maintenance and continuous therapy for multiple myeloma
    Richardson, Paul G.
    Laubach, Jacob
    Gandolfi, Sara
    Facon, Thierry
    Weisel, Katja
    O'Gorman, Peter
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (08) : 751 - 764
  • [22] Consolidation and maintenance therapy of multiple myeloma
    Zojer, N.
    Ludwig, H.
    ONKOLOGE, 2014, 20 (03): : 242 - 249
  • [23] The role of maintenance therapy in multiple myeloma
    B Lipe
    R Vukas
    J Mikhael
    Blood Cancer Journal, 2016, 6 : e485 - e485
  • [24] SAFETY AND TOXICITY OF ANTIARRHYTHMIC DRUG-THERAPY - BENEFIT VERSUS RISK
    PODRID, PJ
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 : S65 - S73
  • [25] A RISK-BENEFIT ASSESSMENT OF CONVENTIONAL VERSUS INTENSIVE INSULIN THERAPY
    REICHARD, P
    DRUG SAFETY, 1994, 10 (03) : 196 - 202
  • [26] Posttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma
    Reece, Donna E.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2011, : 197 - 204
  • [27] Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitis
    Blumenstein, I.
    Xuan, S.
    Panaccione, R.
    Baert, F.
    Barreiro-de Acosta, M.
    Ye, B. D.
    Klaff, J.
    Vladea, R.
    Levy, G.
    Holweg, C. T. J.
    Gonzalez, Y. Sanchez
    Dubinsky, M. C.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I333 - I334
  • [28] RISK VERSUS BENEFIT IN MAMMOGRAPHY
    LESTER, RG
    RADIOLOGY, 1977, 124 (01) : 1 - 6
  • [29] The Risk versus Benefit of LUCAS
    Frascone, Ralph J.
    ANESTHESIOLOGY, 2014, 120 (04) : 797 - 798
  • [30] What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?
    Scott, Emma
    Reece, Donna
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2011, : 205 - 207
12345